Branded Legacy (OTC: BLEG) today announced updates as it confronts recent challenges and charts a focused path forward. In the announcement, the company reaffirmed its commitment to the biotech and wellness sectors, with its primary focus on expanding its wholly owned subsidiary, Sycamore BioPharma. “These challenges have only strengthened our resolve,” stated Branded Legacy CEO Dave Oswald. “While the actions of former employees have created significant hurdles, our commitment to growth and innovation remains unwavering. By focusing on our more successful subsidiaries and securing the necessary funding to expand, we are poised to recover and achieve even greater success in the biotech and wellness industries.”
To view the full press release, visit https://ibn.fm/dFfAV
About Branded Legacy Inc.
Branded Legacy is a forward-thinking company specializing in the development and commercialization of biotech and wellness products. With a focus on strategic growth, innovation and quality, the company is dedicated to enhancing lives and creating sustainable value for its shareholders. For more information, visit the company’s website at https://BrandedLegacy.com.
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
HeartBeam (NASDAQ: BEAT) is developing technology aimed at improving how cardiac conditions are identified and monitored,…
Disseminated on behalf of SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) and may include paid advertising. SureNano Science…
BioAdaptives (OTC: BDPT) a science-driven health and wellness company, announced the launch of MyndSystem, a dual-phase cognitive support…
Sunshine Biopharma (NASDAQ: SBFM) announced the closing of its previously announced public offering, generating approximately $6 million in…
Cardio Diagnostics Holdings (NASDAQ: CDIO), took the spotlight in the latest episode of The BioMedWire Podcast, featuring CEO…
Annovis Bio (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company developing buntanetap for neurodegenerative diseases,…